Research programme: MOR 101 antibodies - MorphoSysAlternative Names: MOR 101 antibodies (Fab fragment); MOR 101 antibodies research programme - MorphoSys; MOR101
Latest Information Update: 16 Mar 2006
At a glance
- Originator MorphoSys
- Mechanism of Action Intercellular adhesion molecule 1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Burns
Most Recent Events
- 24 Feb 2006 Discontinued - Preclinical for Burns in Germany (unspecified route)
- 16 May 2005 This programme is still in active development - (BioSquare-2005)
- 27 Jun 2003 MOR 101 is available for licensing (http://www.morphosys.com)